Introduction {#s1}
============

A recurring theme in treatment of cancer is the acquisition of drug resistance. The effectiveness of therapies targeting specific mutations in receptor tyrosine kinases (RTKs) is limited by the acquisition of resistance to the drugs over the course of treatment ([@bib11]; [@bib1]). Resistance can be acquired through new mutations that block the action of the RTK inhibitors or their uptake and/or genetic amplification of downstream target genes of the RTK ([@bib3]; [@bib5]; [@bib17]; [@bib4]; [@bib22]). Several studies, including this work by Wilson and colleagues, elucidated another mechanism for this acquisition of resistance: the engagement of parallel RTK signaling pathways that converge on common downstream survival signals via signals from the tumor microenvironment. In this study, Wilson and colleagues examined several cancer cell lines for ligand-mediated drug resistance ([@bib20]).

In Figure 2B/C, Wilson and colleagues demonstrated that resistance to primary kinase inhibitor treatment can be induced by the addition of rescuing ligands that activate the PI(3)K--AKT and MAPK pro-survival signaling pathways. This resistance can be overcome with the addition of an appropriate secondary kinase inhibitor. Three different cancer cell line models were used to demonstrate this phenomenon. Treatment of A204 (a *PDGFR* amplified rhabdomyosarcoma cell line) with the ligand FGF activated pFRS2 and pERK, inducing resistance to sunitinib. The addition of a secondary kinase inhibitor, PD173074, blocked FGF-induced pFRS2 and pERK activation, restoring sensitivity to sunitinib. The treatment of M14 (a *BRAF*-mutated melanoma cell line) with the ligand NRG1 activated pHER3 and pAKT, inducing partial resistance to PLX4032. The addition of a secondary kinase inhibitor, lapatinib, blocked NRG1-induced pHER3 and pAKT activation, restoring sensitivity to PLX4032. Treatment of KHM-3S (an *EGFR*-mutated small cell lung cancer cell line) with the ligand HGF activated pMET and pERK, inducing resistance to Erlotinib. The addition of a secondary kinase inhibitor, crizotinib, blocked HGF-induced pMET and pERK activation, restoring sensitivity to erlotinib.

The cell viability assays examining drug sensitivity and the Western blots examining levels of phosphorylated kinases in Figures 2B and 2C, respectively, are the key experiments that demonstrate that growth factor ligands can reactivate downstream signaling components important for cancer cell survival, causing resistance to anticancer kinase inhibitors ([@bib20]). These experiments are replicated in Protocols 1 and 2.

Two studies published around the same time as the work of Wilson and colleagues also support the proposed mechanism of acquired resistance to RTK inhibition by signaling from the tumor microenvironment. Straussman and colleagues demonstrated that HGF signaling derived from the tumor microenvironment could bypass EGFR inhibition by activation of MET signaling ([@bib18], also included for replication in the Reproducibility Project: Cancer Biology), and Harbinski and colleagues, in an approach similar to Wilson and colleagues, showed that multiple growth factor ligands could 'bypass' inhibitor-targeted RTKs ([@bib6]).

Since the publication of Wilson and colleagues\' work, several publications have reported similar results to those being replicated in Protocols 1 and 2. Similar to the experiments with A204 cells above, Welti and colleagues demonstrated that FGF ligands could induce resistance to sunitinib, which could be reversed by the addition of PD173074 ([@bib19]). These experiments were performed in HUVEC cells, whereas A204 cells were used in the study being replicated. Similar to the experiments on M14 cells above, Montero-Conde and colleagues showed that NRG1 ligand could activate pHER3 and pAKT in the presence of PLX4032, and this activation could be reversed by the addition of lapatinib ([@bib12]). These experiments were performed in 8505C cells, whereas M14 cells were used in the study being replicated. Similar to the experiments performed on KHM-S3 cells above, several groups have demonstrated that HGF ligand can induce resistance to erlotinib and that this resistance can be reversed by the addition of crizotinib ([@bib14]; [@bib13]). These experiments were performed in PC-9 and HCC827 cells, whereas KHM-3S cells were used in the study being replicated.

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: Cell viability assays {#s2-1}
---------------------------------

This protocol describes cell viability assays to determine the IC~50~ values of three cancer cell lines treated with primary kinase inhibitor alone, primary kinase inhibitor in combination with rescuing ligand, and primary kinase inhibitor in triple combination with rescuing ligand and a drug targeting the rescuing ligand\'s receptor tyrosine kinase (RTK) (termed the secondary kinase inhibitor) (Figure 2B).

### Sampling {#s2-1-1}

The original data presented is qualitative, and the authors were unable to share the raw data values with the RP:CB core team. This prevents power calculations being performed a priori to determine the sample size (number of biological replicates). In order to determine an appropriate number of replicates to perform initially, we have estimated the sample sizes required based on a range of potential variance. We will also determine the sample size *post hoc* as described in Power Calculations.Please see Power Calculations for details.Each experiment has three cohorts. In each cohort, a dilution series of the primary kinase inhibitor (10^−4^, 10^−3^, 10^−2^, 10^−1^, 10^0^, and 10^1^ µM) is run three times; once alone, once with the rescuing ligand, and once with both the rescuing ligand and the secondary kinase inhibitor. The effect of the secondary kinase inhibitor alone will also be assessed. Each condition will be run in triplicate.Cohort 1: A204 cell line.Media only \[additional\].Vehicle control.0.001 µM--10 µM sunitinib + no ligand.0.001 µM--10 µM sunitinib + 50 ng/ml FGF.0.001 µM--10 µM sunitinib + 50 ng/ml FGF + 0.5 µM PD173074.0.5 µM PD173074 + no ligand \[additional\].Cohort 2: M14 cell line.Media only \[additional\].Vehicle control.0.001 µM--10 µM PLX4032 + no ligand.0.001 µM--10 µM PLX4032 + 50 ng/ml NRG1.0.001 µM--10 µM PLX4032 + 50 ng/ml NRG1 + 0.5 µM lapatinib.0.5 µM lapatinib + no ligand \[additional\].Cohort 3: KHM-3S cell line.Media only \[additional\].Vehicle control.0.001 µM--10 µM erlotinib + no ligand.0.001 µM--10 µM erlotinib + 50 ng/ml HGF.0.001 µM--10 µM erlotinib + 50 ng/ml HGF + 0.5 µM crizotinib.0.5 µM crizotinib + no ligand \[additional\].

### Materials and reagents {#s2-1-2}

ReagentTypeManufacturerCatalog \#Comments96-well tissue culture platesMaterialsCorning (Sigma-Aldrich)CLS3516Original unspecifiedKHM-3S cellsCellsJCRB Cell BankJCRB0138Original source of the cells unspecifiedA204CellsATCCHTB-82Original source of the cells unspecifiedM14CellsATCCHTB-129[\*](#tblfn1){ref-type="table-fn"}Original source of the cells unspecifiedLapatinibDrugLC LaboratoriesL-4804Original formulation unspecifiedCrizotinibDrugSigma-AldrichPZ0191Originally from Selleck ChemicalsPD173074DrugSigma-AldrichP2499Originally from Tocris BiosciencePLX4032DrugActive BiochemA-1130SunitinibDrugSigma-AldrichPZ0012Originally from Selleck Chemicals, formulation unspecifiedErlotinibDrugLC LaboratoriesE-4007HGFLigandSigma-AldrichH5791Originally obtained from PeprotechFGF-basicLigandSigma-AldrichF0291Originally obtained from PeprotechNRG1-β1LigandNovus BiologicalsH00003084-P01Originally obtained from R&D SystemsRPMI 1640MediaSigma-AldrichR8758Originally from Gibco, formulation unspecifiedFBSReagentSigma-AldrichF4135Originally from GibcoPenicillinAntibioticSigma-AldrichP4458Original unspecifiedStreptomycinAntifungalOriginal unspecifiedParaformaldehydeReagentSigma-Aldrich158127Original unspecifiedSyto 60ReagentLife TechnologiesS11342Original unspecifiedOdyssey scannerEquipmentLiCOROdyssey application softwareSoftwareLiCOR[^1]

### Procedure {#s2-1-3}

#### Notes {#s2-1-3-1}

All cells will be sent for mycoplasma testing and STR profiling.Medium for all cell lines: RPMI 1640 supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin.Cells maintained at 37°C in a humidified atmosphere at 5% CO~2~.Seed 3000--5000 cells per well into 96-well plates. For each condition replicate seed 1 well as the media control, 1 well as the vehicle control, 1 well for treatment with the secondary kinase inhibitor alone, and 6 wells per concentration curve (10^−4^, 10^−3^, 10^−2^, 10^−1^, 10^0^, and 10^1^ µM), of which there are three.a. 6 wells per concentration curve × 3 concentration curves = 18 wells + 3 wells = 21 wells per cohort.18--24 hr after seeding treat 3 wells per condition with appropriate treatment (see Sampling).a. Lab will record the vehicle used to solubilize the drugs.72 hr after treatment, fix cells in 4% paraformaldehyde (PFA).a. Lab will record the PFA incubation time.Stain with Syto 60 according to the manufacturer\'s recommendations and assay cell number using an Odyssey with Odyssey Application Software.a. Include empty wells and media only wells.Calculate cell viability by dividing the fluorescence from the drug-treated cells by the fluorescence from the control (vehicle) treated cells. Fit normalized data to a sigmoidal dose--response curve.a. Also calculate the effect of vehicle by dividing the fluorescence from the control vehicle cells by the fluorescence from the media only treated cells \[additional control\].b. Determine the IC~50~ values for each curve.c. Lab will document the software used to fit the data to a sigmoidal dose--response curve and calculate the IC~50~ values.Repeat independently two additional times.

### Deliverables {#s2-1-4}

Data to be collected:Raw fluorescence data and calculated cell viability.Semi-logarithmic graph for each condition of primary kinase inhibitor (log) vs normalized cell viability (linear) for each cell line \[comparable to Figure 2B\].Calculated IC~50~ for each condition.

### Confirmatory analysis plan {#s2-1-5}

Statistical analysis of the Replication Data:For each cell line compare the IC~50~ of primary kinase inhibitor alone, primary kinase inhibitor + ligand, and primary kinase inhibitor + ligand + secondary kinase inhibitor.• ANOVA.Meta-analysis of original and replication attempt effect sizes:We will plot the replication data (mean and 95% confidence interval) and will include the original data point, calculated directly from the representative image in Figure 2B, as a single point on the same plot for comparison.

### Known differences from the original study {#s2-1-6}

We are including two additional control conditions;Media alone.a. To provide a baseline.Treatment of the cells with the secondary kinase inhibitor alone.a. To assess any effects, the secondary kinase inhibitor may be independent of the ligand and primary kinase inhibitor.

### Provisions for quality control {#s2-1-7}

All data obtained from the experiment---raw data, data analysis, control data, and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/h0pnz/>).Cell lines will be validated by STR profiling and screened for mycoplasma contamination.A lab from the Science Exchange network with extensive experience in conducting cell viability assays will perform these experiments.

Protocol 2: Western blot assays {#s2-2}
-------------------------------

This protocol describes Western blot assays to determine the levels of activated phosphorylated signaling pathways in three cancer cell lines treated with primary kinase inhibitor alone, primary kinase inhibitor in combination with rescuing ligand, and primary kinase inhibitor in triple combination with rescuing ligand and a drug targeting the rescuing ligand\'s receptor tyrosine kinase (RTK) (termed the secondary kinase inhibitor) (Figure 2C).

### Sampling {#s2-2-1}

The original data presented is qualitative. This prevents power calculations being performed a priori to determine the sample size (number of biological replicates). In order to determine an appropriate number of replicates to perform initially, we have estimated the sample sizes required based on a range of potential variance. We will also determine the sample size *post hoc* as described in Power Calculations.Please see Power Calculations for details.Each experiment has three cohorts. Each cohort will consist of cells treated with media alone, with vehicle alone, with the primary kinase inhibitor, with primary kinase inhibitor and the rescuing ligand and with the primary kinase inhibitor, the rescuing ligand and the secondary kinase inhibitor. The effect of the secondary kinase inhibitor alone will also be assessed. Each condition will be run once (i.e., no technical replicates will be performed).Cohort 1: A204 cell line.Media only \[additional\].Vehicle control.1 µM sunitinib + no ligand.1 µM sunitinib + 50 ng/ml FGF.1 µM sunitinib + 50 ng/ml FGF + 0.5 µM PD173074.1 µM PD173074 + no ligand \[additional\].Cohort 2: M14 cell line.Media only \[additional\].Vehicle control.1 µM PLX4032 + no ligand.1 µM PLX4032 + 50 ng/ml NRG1.1 µM PLX4032 + 50 ng/ml NRG1 + 0.5 µM lapatinib.1 µM lapatinib + no ligand \[additional\].Cohort 3: KHM-3S cell line.Media only \[additional\].Vehicle control.1 µM erlotinib + no ligand.1 µM erlotinib + 50 ng/ml HGF.1 µM erlotinib + 50 ng/ml HGF + 0.5 µM Crizotinib.1 µM crizotinib + no ligand \[additional\].Cohort 4: positive control cell lines.For Cohort 1: HL60 cells treated with FGF \[additional control\].For Cohort 2: MCF7 cells treated with NRG1 \[additional control\].For Cohort 3: HEK293 cells treated with HGF \[additional control\].a. Treatment of these cell lines with their cognate growth factor ligands will serve as a positive control for ligand activity.

### Materials and reagents: {#s2-2-2}

ReagentTypeManufacturerCatalog \#Comments96-well Tissue culture platesMaterialsCorning (Sigma-Aldrich)CLS3596Original unspecified6-well tissue culture platesMaterialsCorning (Sigma-Aldrich)CLS3516Original unspecifiedKHM-3S cellsCellsJCRB Cell BankJCRB0138Original source of the cells unspecifiedA204 cellsCellsATCCHTB-82Original source of the cells unspecifiedM14 cellsCellsATCCHTB-129Original source of the cells unspecifiedHL60 cellsCellsATCCCCL-240MCF7 cellsCellsATCCHTB-22HEK293 cellsCellsATCCCRL-1573LapatinibDrugLC LaboratoriesL-4804Original formulation unspecifiedCrizotinibDrugSigma-AldrichPZ0191Originally from Selleck ChemicalsPD173074DrugSigma-AldrichP2499Originally from Tocris BiosciencePLX4032DrugActive BiochemA-1130SunitinibDrugSigma-AldrichPZ0012Originally from Selleck Chemicals, formulation unspecifiedErlotinibDrugLC LaboratoriesE-4007HGFLigandSigma-AldrichH5791Originally obtained from PeprotechFGF-basicLigandSigma-AldrichF0291Originally obtained from PeprotechNRG1-β1LigandNovus BiologicalsP1426Originally obtained from R&D SystemsRPMI 1640MediaSigma-AldrichR8758Originally from Gibco, formulation unspecifiedFBSReagentSigma-AldrichF4135Originally from GibcoPenicillinAntibioticSigma-AldrichP4458Original unspecifiedStreptomycinAntifungalOriginal unspecifiedHalt protease and phosphatase cocktail inhibitorReagentThermo Scientific78440Image JSoftwareNational Institutes of Health (NIH)N/Ap-PDGFRαAntibodySanta CruzSC-12911190 kDaPDGFRαAntibodyCell Signaling5241190 kDap-AKT S473AntibodyInvitrogen44-621 G65 kDaAKTAntibodyCell Signaling927265 kDap-ERK T202/Y204AntibodyCell Signaling910144,42 kDaERKAntibodyCell Signaling910244,42 kDapFRS2α Y196AntibodyCell Signaling386485 kDaFRS2αAntibodySanta CruzSC-831885 kDaβ-tubulinAntibodyCell Signaling214655 kDapHER3 Y1289AntibodyCell Signaling4791185 kDaHER3AntibodySanta CruzSC-285185 kDap-EGFR Y1068AntibodyAbcamab5644185 kDaEGFRAntibodyBD Biosciences610017185 kDap-MET Y1234/5AntibodyCell Signaling3126145 kDaMETAntibodySanta CruzSC-10145 kDaAnti-Mouse IgG-HRPAntibodyCell Signaling Technology7076P2Original unspecifiedAnti-Rabbit IgG-HRPAntibodyCell Signaling Technology7074P2Original unspecifiedAnti-Goat IgG-HRPAntibodySanta Cruz Biotechnologysc-2020Original unspecifiedTrypsin-EDTA solution (1X)ReagentSigma-AldrichT3924Original unspecifiedDulbecco's Phosphate Buffered SalineReagentSigma-AldrichD1408Original unspecifiedMini Protean TGX 4--15% Tris-Glycine gels; 15-well; 15 μlReagentBio-Rad456-1086Original unspecified2X Laemmli sample bufferReagentSigma-AldrichS3401Original unspecifiedECL DualVue Western Markers (15 to 150 kDa)ReagentSigma-AldrichGERPN810Original unspecifiedNitrocellulose membrane; 0.45 μm, 20 × 20 cmReagentBio-Rad162-0113Original unspecifiedPonceau SReagentSigma-AldrichP7170Original unspecifiedTris Buffered Saline (TBS); 10X solutionReagentSigma-AldrichT5912Original unspecifiedTween 20ReagentSigma-AldrichP1379Original unspecifiedNonfat-Dried MilkReagentSigma-AldrichM7409Original unspecifiedSuper Signal West Pico SubstrateReagentThermo-Fisher (Pierce)34087

### Procedure {#s2-2-3}

#### Notes {#s2-2-3-1}

All cells will be sent for mycoplasma testing and STR profiling.Medium for cell lines: RPMI 1640 supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin.MCF7 cells and HEK293 cells are maintained in DMEM + 10% FBS.Cells maintained at 37°C in a humidified atmosphere at 5% CO~2~.Seed cells in plates.a. Two control and four experimental wells (6 wells total) are needed for each cell line in Cohorts 1--3.i. Lab will determine and record the number of cells seeded and well size used.b. \*For Cohort 4 seed cells as needed into wells of a 6-well plate.18--24 hr after seeding treat wells in Cohorts 1--3 with conditions as described in the Sampling section.a. Lab will determine and record vehicle for preparation of drug solutions.b. Harvest protein as in Step 5 after 2 hr of treatment.Simultaneously treat cells in Cohort 4 as follows:a. HL60 cells. Note: This protocol is based on [@bib9].i. Serum starve HL60 cells for 24 hr prior to protein harvesting.Serum starve = DMEM + 0% FBS.ii. Treat cells for 10 min with 100 ng/ml FGF.iii. Harvest cell lysates as noted in Step 5.b. MCF7 cells. Note: This protocol is based on [@bib16].i. Serum starve cells for 48 hr prior to protein harvesting.Serum starve = DMEM + 0.1% BSA.ii. Treat cells with 1 nmol/l NRG1 for 10 min at 37°C.iii. Harvest cell lysates as noted in Step 5.c. HEK293 cells. Note: This protocol is based on [@bib21].i. Serum starve HEK293 cells for 24 hr prior to protein harvesting.Serum starve = DMEM + 0% FBS.ii. Treat cells with 29 ng/ml HGF for 10 min at 37°C.iii. Harvest cell lysates as noted in Step 5.^\#^Preparation of cell lysate:a. Note: from here on, the replicating lab will use their in-house Western blot protocol, as recommended by the original authors.b. Harvest cells from the tissue culture plate using 1× trypsin--EDTA.c. Wash cells with 1× cold PBS and spin at 1200 rpm for 5 min.d. Decant the PBS and add lysis buffer to the cell pellet and resuspend well.e. Incubate at room temperature for 5 min.f. Spin solution at 13,000 rpm for 30 min at 4°C using a benchtop centrifuge.g. Collect the lysate/protein sample and store at −20°C or −80°C for later use.^\#^SDS-PAGE separation:a. Prepare the lysate sample by adding SDS reducing loading dye to ∼25--30 µg of protein sample and boiling at 95°C--100°C for 5 min.i. Lab will record exact amount of protein loaded and provide data from determining protein concentration.b. Let samples cool on ice and quick-spin the tubes to collect any droplets on the cap of the tube.c. Prepare the gel for sample loading---insert the gel in the gel box with 1× running buffer and ensure there is no leak.i. Based on the expected MWs of the targets, lab will determine the optimal percentage gel to use.d. Load 16 µl of sample (25--30 µg/lane) in each well of the Tris--glycine gel.e. Run the sample at 175 V for 25 min.f. Remove the gel from the cassette and rinse with water.^\#^Transfer and blocking:a. Transfer protein on the gel to a nitrocellulose membrane for 1 hr at 12 V using a semi-dry transfer apparatus, 1× transfer buffer, and blotting sheets.b. Verify the efficiency of the transfer by Ponceau staining of the membrane.i. Lab will record an image of the Ponceau-stained membrane.c. Incubate the blots in 5% non-fat skim milk for 1 hr at room temperature.^\#^Antibody probing:a. Dilute the primary antibodies according to the manufacturer\'s recommendations, as suggested by the original authors.i. If the manufacturer recommends a range of dilutions, lab will use a dilution in the middle of the recommended dilution range.ii. A204:p-PDGFRα.PDGFRα.p-AKT S473.AKT.p-ERK T202/Y204.ERK.pFRS2α Y196.FRS2α.β-tubulin \[additional control\].A. Loading control.iii. M14:pHER3 Y1289.HER3.p-AKT S473.AKT.p-ERK T202/Y204.ERK.β-tubulin \[additional control\].A. Loading control.iv. KHM-3S:p-EGFR Y1068.EGFR.p-AKT S473.AKT.p-ERK T202/Y204.ERK.p-MET Y1234/5.MET.β-tubulin \[additional control\].A. Loading control.v. HL60:pERK T202/Y204.ERK.β-tubulin \[additional control\].A. Loading control.vi. MCF7:pHER3.HER3.β-tubulin \[additional control\].A. Loading control.vii. HEK293:pMET.MET.β-tubulin \[additional control\].A. Loading control.b. Add the antibody solutions to the membranes and incubate them for 12--16 hr at 4°C.c. Wash the blots with Tris-buffered saline (TBS) and with 0.5% Tween-20 three times for 10 min each.d. Dilute HRP-secondary antibody in 5% milk and add to the blots.i. Lab will record the dilution factor of the secondary antibody.e. Incubate at room temperature for 1 hr.f. Wash the blots with TBS +0.5% Tween-20 four times for 15 min each.^\#^Developing:a. Remove as much wash buffer as possible.b. Mix Super Signal West Pico Chemiluminescent Substrate solutions in equal proportions and add it to the blot.c. Incubate for ∼1 min.d. Insert the blot in the developing cassette and develop the blot in the dark.e. Expose the blot to the film at three time points, starting with 15 s. Determine the other two time points based on the strength of the signal in the 15 s exposure.^\#^Scan film and quantify band intensity using densitometric analysis software.Repeat independently two additional times.

### Deliverables {#s2-2-4}

Data to be collected:Images of probed membranes (images of full films with molecular weight ladders).Scanned image of Ponceau-stained membranes after protein transfer.Quantified signal intensities and bar graphs of mean signal intensities normalized for β-tubulin loading and total pan-protein levels.

### Confirmatory analysis plan {#s2-2-5}

Statistical analysis of the Replication Data:For each cell line compare the following normalized phosphorylated kinase levels of primary kinase inhibitor alone, primary kinase inhibitor + ligand, and primary kinase inhibitor + ligand + secondary kinase inhibitor.• One-way ANOVA.• Note: at the time of analysis, we will generate a histogram of all the data to determine if it follows a Gaussian distribution or not. If it is skewed, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis.Meta-analysis of original and replication attempt effect sizes:We will plot the replication data (mean and 95% confidence interval) and will include the original data point, calculated directly from the representative image in Figure 2C, as a single point on the same plot for comparison.

### Known differences from the original study {#s2-2-6}

We are including three additional control conditions;Media alone.i. To provide a baseline.Treatment of the cells with the secondary kinase inhibitor alone.i. To assess any effects, the secondary kinase inhibitor may be independent of the ligand and primary kinase inhibitor.Treatment of a control cell line with the growth factor ligand alone.i. To ensure the growth factor ligand is active.FGF should cause phosphorylation of ERK1/2 in HL60 cells.NRG1 should cause phosphorylation of HER3 in MCF7 cells.HGF should cause phosphorylation of MET in HEK293 cells.The original authors recommended that the replicating lab follows a standard Western blot protocol.

### Provisions for quality control {#s2-2-7}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/h0pnz/>).Cell lines will be validated by STR profiling and screened for mycoplasma contamination.A lab from the Science Exchange network with extensive experience in conducting Western blot assays for phosphorylated proteins will perform these experiments.

Power Calculations {#s2-3}
------------------

### Protocol 1 {#s2-3-1}

The original data presented is qualitative (images of survival curves) and the authors were unable to share the raw data values with the RP:CB core team. To estimate original effect sizes, we determined approximate IC~50~ concentrations from the original survival curve images.

Summary of the original data.A204 cellsIC~50~Sunitinib0.05 μMSunitinib + FGF2.5 μMSunitinib + FGF + PD1730740.025 μM[^2][^3]M14IC~50~PLX40320.1 μMPLX4032 + NRG10.2 μMPLX4032 + NRG1 + Lapatinib0.1 μM[^4][^5]KHM-3SIC~50~Erlotinib0.5 μMErlotinib + HGF\>10 μMErlotinib + HGF + Crizotinib0.3 μM[^6][^7]

We have calculated the projected sample size based on a variety of different possible levels of variance using a one-way ANOVA test with an alpha error of 0.05.These power calculations were performed with G\*Power software, version 3.1.7 ([@bib3a]).The F statistic was calculated at <http://statpages.org/anova1sm.html>.The η~P~^2^ was calculated using the formula on the spreadsheet accessed from Lakens and colleagues ([@bib10]).A204VarianceF (2, 6)η~P~^2^Effect size *f*PowerTotal sample size across all groups2%7273.61320.99958849.2563199.99%615%129.30870.9773266.56531699.99%628%37.11030.9252063.51710998.53%640%18.1840.8583842.46198185.32%6

For each percent variance, the relative standard deviation of the approximated IC~50~ was used to calculate the F statistic from a one-way ANOVA analysis, which was converted to η~P~^2^ (the ratio of variance attributed to the effect and the effect plus its associate error variance from the ANOVA), and then used to determine the effect size (Cohen\'s *f*) and the needed sample size to obtain at least 80% power. The actual power obtained is listed.M14VarianceF (2, 6)η~P~^2^Effect size *f*PowerTotal sample size across all groups2%12500.99760620.413599.99%615%22.22220.8810572.72165290.90%628%6.37760.6800891.45803685.39%940%3.1250.5102041.02062188.33%15KHM-S3VarianceF (2, 6)η~P~^2^Effect size *f*PowerTotal sample size across all groups2%6890.82120.99956547.935999.99%615%122.50350.9760966.39014999.99%628%35.15730.9213783.42331598.12%640%17.22710.8516842.39632283.59%6

In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify the IC~50~. We will determine the standard deviation of the IC~50~ across the three biological replicates and combine this with the means from the original study to simulate an effect size. Using this simulated effect size, we will then determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

### Protocol 2 {#s2-3-2}

The original data presented is qualitative (images of Western Blots). We used Image Studio Lite v. 4.0.21 (LICOR) to perform densitometric analysis of the presented bands to quantify the original effect size. Levels of phospho-protein were normalized to total protein and then normalized to the control.

Summary of original data.A204 cellspPDGFRpAKTpERKpFRS2Control1111Sunitinib alone0.2640.08451.9521.473Sunitinib + FGF0.3370.0925.3508.069Sunitinib + FGF + PD1730740.3040.0710.3691.013[^8][^9]M14 cellspHER3pAKTpERKControl111PLX4032 alone0.36671.86450.0524PLX4032 + NRG13.944711.2110.0539PLX4032 + NRG1 + Lapatinib1.06661.78630.0571[^10][^11]KHM-3S cellspEGFRpAKTpERKpMETControl1111Erlotinib alone0.0080.6090.181.098Erlotinib + HGF0.0141.3810.97911.66Erlotinib + HGF + Crizotinib0.0230.4170.0851.095[^12][^13]

We have calculated the projected sample size based on a variety of different possible levels of variance ([@bib8]) using a one-way ANOVA test with an alpha error of 0.05.These power calculations were performed with G\*Power software, version 3.1.7 (Faul et al., 2007).The F statistic was calculated at <http://statpages.org/anova1sm.html>.The η~P~^2^ was calculated using the formula on the spreadsheet accessed from Lakens and colleagues ([@bib10]).A204 cells2% VariancepPDGFRpAKTpERKpFRS2F(3, 8)2884.51336189.00644400.83415183.0738η~p~²0.9990763770.9995693140.9993944210.999485769Effect size *f*32.889148.1754840.6240344.08686Power99.99%99.99%99.99%99.99%Total sample size across all groups888815% variancepPDGFRpAKTpERKpFRS2F(3, 8)51.28023644110.026780478.2370506792.14353422η~p~²0.9505686790.9763369860.9670390090.971873631Effect size *f*4.3852126.4233985.4165395.87825Power99.99%99.99%99.99%99.99%Total sample size across all groups888828% variancepPDGFRpAKTpERKpFRS2F(3, 8)14.7169045931.5765632722.453235226.44425408η~p~²0.8465984560.9221257260.8938424730.908396348Effect size *f*2.3492213.4411062.9017173.149063Power91.97%99.79%98.43%99.35%Total sample size888840% variancepPDGFRpAKTpERKpFRS2F(3, 8)7.2112832515.47251611.0020852512.9576845η~p~²0.730038450.8529885980.8049078160.829326246Effect size *f*1.6444552.4087742.0312022.204344Power96.95%93.12%83.18%88.55%Total sample size across all groups12888

For each percent variance, the relative standard deviation of the approximated phospho-protein level was used to calculate the F statistic from a one-way ANOVA analysis, which was converted to η~P~^2^ (the ratio of variance attributed to the effect and the effect plus its associated error variance from the ANOVA), and then used to determine the effect size (Cohen\'s *f*) and the needed sample size to obtain at least 80% power. The actual power obtained is listed.M14 cells2% VariancepHER3pAKTpERKF(3, 8)4297.46015283.29946645.7378η~p~²0.9993798630.999495520.999598901Effect size *f*40.1440844.5111149.92144Power99.99%99.99%99.99%Total sample size across all groups88815% variancepHER3pAKTpERKF(3, 8)76.3992906793.92532267118.1464498η~p~²0.9662728850.9723924660.977927341Effect size *f*5.3525455.9348126.656194Power99.99%99.99%99.99%Total sample size across all groups88828% variancepHER3pAKTpERKF(3, 8)21.9258168426.9556091833.90682551η~p~²0.8915657840.9099776570.927087448Effect size *f*2.8674353.1793643.565818Power98.24%99.42%99.88%Total sample size88840% variancepHER3pAKTpERKF(3, 8)10.7436502513.208248516.6143445η~p~²0.8011481250.83202010.861694667Effect size *f*2.0072042.2255552.496073Power82.32%89.11%94.57%Total sample size across all groups888KHM-S3 cells2% VariancepEGFRpAKTpERKpMETF(3, 8)7271.8941594.15613697.78226041.5258η~p~²0.9996334260.9983300170.9992793670.999558805Effect size *f*52.2203224.4501237.23847.59802Power99.99%99.99%99.99%99.99%Total sample size across all groups888815% variancepEGFRpAKTpERKpMETF(3, 8)129.278115628.3405528965.73835022107.4049031η~p~²0.9797895250.9139985230.9610165050.975773338Effect size *f*6.9627073.2600164.9650666.346404Power99.99%99.57%99.99%99.99%Total sample size across all groups888828% variancepEGFRpAKTpERKpMETF(3, 8)37.10158.1334494918.8662357130.82411122η~p~²0.9329446920.7530890750.8761585120.920376091Effect size *f*3.7300221.7464372.6598573.399859Power99.94%98.31%96.62%99.75%Total sample size across all groups8128840% variancepEGFRpAKTpERKpMETF(3, 8)18.1797353.985390259.244455515.1038145η~p~²0.8720802420.599121490.7761196110.84993841Effect size *f*2.6110151.2225061.86192.379901Power96.09%94.83%99.19%92.58%Total sample size across all groups816128

In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the three biological replicates and combine this with the mean from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Registered report: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors" for consideration at *eLife*. Your article has been favorably evaluated by Tony Hunter (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

1\) The experimental design to test the reproducibility of [@bib20] is thorough and well-articulated, with some exceptions. First, it will be important to perform positive controls to assess the performance of the growth factors or the kinase inhibitors that will be used.

2\) Second, given that the western blots in the original manuscript are not quantified and that quantification is derived from the published work, the authors should describe how they are going to determine whether the data are "reproducible" or not.

3\) Third, it is not immediately clear whether the distribution of the data (IC50 for Protocol 1 and band intensity for Protocol 2) will exhibit any skew. Therefore, at the time of analysis, it may be useful to plot histograms of the data to examine their distributions, and, if necessary, consider suitable transformations (for example, the Box--Cox family of transformations) of the data to obtain (approximately) symmetric distributions so that the testing procedures are valid.

4\) Lastly, the authors should either include or explain the reason for excluding in the replication study the role of HGF-MET signaling in resistance to BRAF inhibition that was observed in some melanomas in the original study and other reports.
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Author response

*1) The experimental design to test the reproducibility of* [@bib20] *is thorough and well-articulated, with some exceptions. First, it will be important to perform positive controls to assess the performance of the growth factors or the kinase inhibitors that will be used*.

We agree that verifying the activity of the reagents prior to their use in our experiments is an important step. We have three classes of reagent: primary RTK inhibitors, growth factor ligands, and secondary RTK inhibitors. Each cohort includes a positive control where the cell line of interest is treated solely with its cognate primary RTK inhibitor. This should demonstrate that the drug is active as anticipated, and the quality control data (for both primary and secondary RTK inhibitors) provided by the manufacturers will be included in the materials publicly available through the Open Science Framework. However, as indicated by the reviewers, there is known lot-to-lot variation in growth factors, so we have added steps to test the growth factors we are using for activity. In Protocol 2, we have added in additional cell lines that have a known response to treatment with the ligand alone, as evidenced by phosphorylation of downstream targets. We will treat these positive control cell lines with the growth factors and assess phosphorylation of their cognate target by Western blot. The manuscript has been updated to reflect this additional work.

*2) Second, given that the western blots in the original manuscript are not quantified and that quantification is derived from the published work, the authors should describe how they are going to determine whether the data are "reproducible" or not*.

We will present both the original data and replication data for side-by-side comparison. We will plot the mean value of our replication data along with the 95% confidence interval. We will then include the original data point (IC~50~ or quantified Western blot band intensity) on the same plot to demonstrate if the original data falls within the 95% confidence interval of the replication data. We have also updated the language of the manuscript to reflect this change.

*3) Third, it is not immediately clear whether the distribution of the data (IC50 for Protocol 1 and band intensity for Protocol 2) will exhibit any skew. Therefore, at the time of analysis, it may be useful to plot histograms of the data to examine their distributions, and, if necessary, consider suitable transformations (for example, the Box--Cox family of transformations) of the data to obtain (approximately) symmetric distributions so that the testing procedures are valid*.

Thank you for this suggestion. At the time of analysis, we will generate a histogram of all the data to determine if it follows a Gaussian distribution or not. If it is skewed, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. We will note any changes or transformations made. We have also updated the manuscript to address this point.

*4) Lastly, the authors should either include or explain the reason for excluding in the replication study the role of HGF-MET signaling in resistance to BRAF inhibition that was observed in some melanomas in the original study and other reports*.

We agree that all of the experiments included in the original study are important, and choosing which experiments to replicate has been one of the great challenges of this project. In this case, the RP:CB core team felt that the most impactful information in [@bib20] was that bypassing RTK inhibition by ligand-mediated activation of parallel signaling pathways was a mechanism applicable to many different types of cancer, each with its own constellation of addictive mutations and cognate inhibitors. The experiments addressing the role of HGF in activating MET signaling to bypass EGFR inhibition provide a more detailed exploration of this mechanism in one specific cancer type scenario, and support the larger conclusion drawn from the experiments we chose for replication. As such, we will restrict our analysis to the experiments being replicated and will not include discussion of experiments not being replicated in this study.

[^1]: The breast cancer cell line MDA-MB-435 has been shown to be mislabeled; it is in fact identical to the M14 melanoma cell line ([@bib15]; [@bib2]; [@bib7]).

[^2]: • FGF induces resistance to Sunitinib.

[^3]: • PD173074 blocks FGF-induced resistance to Sunitinib, restoring sensitivity.

[^4]: • NRG1 induces partial resistance to PLX4032.

[^5]: • Lapatinib blocks NRG1-induced resistance to PLX4032, restoring sensitivity.

[^6]: • HGF induces resistance to Erlotinib.

[^7]: • Crizotinib blocks HGF-induced resistance to Erlotinib, restoring sensitivity.

[^8]: • FGF activates pFRS2 and pERK in the presence of Sunitinib.

[^9]: • PD173074 blocks FGF-induced pFRS2 and pERK activation.

[^10]: • NRG1 activates pHER3 and pAKT in the presence of PLX4032.

[^11]: • Lapatinib blocks NRG1-induced pHER3 and pAKT activation.

[^12]: • HGF activates pMET and pERK in the presence of Erlotinib.

[^13]: • Crizotinib blocks HGF-induced pMET and pERK activation.
